Investigational drug · Phase 2
NOC-110
Also called: taplucainium
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Refractory or Unexplained Chronic Cough.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "NOC-110"
First trial start
2024
Sep 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NOC-110", any sponsor or status.
Conditions studied
As listed on its trial records.
- Refractory or Unexplained Chronic Cough
Largest trials
Live from ClinicalTrials.gov: studies naming "NOC-110" as an intervention, largest first.
- Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic CoughPivotal-lookingActive, not recruiting
Nocion TherapeuticsIndustry
NCT06504446 · 455 participants (planned) · Start Sep 24, 2024 · Primary completion Jun 15, 2026
Drug: NOC-110 · For: Refractory or Unexplained Chronic Cough
Sites: Foley, Alabama; Scottsdale, Arizona; Tempe, Arizona · 106 sites in all
Nocion TherapeuticsIndustry
NCT05628740 · 24 participants · Start Feb 7, 2022 · Primary completion Oct 25, 2022
Drug: 3 mg NOC-100 (via nebulizer); 1 mg NOC-110 (via DPI) [1x 1 mg capsule] and 4 more · For: Refractory Chronic Cough
Sites: Phoenix, Arizona; Leesburg, Florida; Winter Park, Florida
Newest research
PubMed records naming it or its code names, newest first.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.